US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global X Silver Miners ETF

48.70

+0.20800.43%

Volume:587.28K

Turnover:28.59M

Market Cap:1.95B

PE:-8.27

High:48.99

Open:48.95

Low:48.47

Close:48.49

Loading ...

Overview Company News Filings

Hi Ho Silver as SIL, SLV, SIVR Keep Shining on Higher Prices

Promising Future for Silexion Therapeutics: Buy Rating Reiterated Due to SIL-204’s Potential in KRAS-Mutated Cancers

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Americas Gold & Silver to Be Included in Solactive Global Silver Miners Index (SIL)

BUZZ-Silver miners fall after Trump's tariffs raise demand concerns

ETF investors appear hungry for international stocks despite looming tariffs

Global X Silver Miners ETF (SIL): Among The Best Global ETFs To Buy

Have You Missed Out on Gold's Record Run? Take a Look at Silver

Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results

Hexagon ramps up ADAS software innovation with cloud-native quality test automation solution

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics reports preclinical data for SIL-204

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SIL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SIL\",,,,,undefined,":{"symbol":"SIL","market":"US","secType":"STK","nameCN":"Global X Silver Miners ETF","latestPrice":48.698,"timestamp":1749826863512,"preClose":48.49,"halted":0,"volume":587277,"delay":0,"floatShares":40097318,"shares":40097318,"eps":-5.89,"marketStatus":"Trading","change":0.208,"latestTime":"06-13 11:01:03 EDT","open":48.95,"high":48.9899,"low":48.47,"amount":28589219.891459998,"amplitude":0.010722,"askPrice":48.71,"askSize":1000,"bidPrice":48.68,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":-5.89,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749844800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":48.49,"sharesOutstanding":40097318,"nav":47.87,"aum":1919470043.14,"dividendRate":0.015606,"bidAskSpread":0.000435,"preHourTrading":{"tag":"盘前","latestPrice":48.9,"preClose":48.49,"latestTime":"09:29 EDT","volume":2651,"amount":129570.83271,"timestamp":1749821399999},"postHourTrading":{"tag":"盘后","latestPrice":48.51,"preClose":48.48,"latestTime":"19:59 EDT","volume":1749,"amount":84947.738,"timestamp":1749772766148},"volumeRatio":1.28351,"impliedVol":0.3719,"impliedVolPercentile":0.232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SIL\",,,,,undefined,":{"symbol":"SIL","floatShares":40097318,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.28351,"shares":40097318,"dividePrice":0.76,"high":48.9899,"amplitude":0.010722,"preClose":48.49,"low":48.47,"week52Low":28.02,"pbRate":"--","week52High":49.76,"institutionHeld":0,"latestPrice":48.698,"eps":-5.89,"divideRate":0.015606,"volume":587277,"delay":0,"ttmEps":-5.89,"open":48.95,"prevYearClose":31.77,"prevWeekClose":48.36,"prevMonthClose":43.15,"prevQuarterClose":39.45,"fiveDayClose":48.36,"twentyDayClose":39.58,"sixtyDayClose":40.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SIL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542134893","title":"Hi Ho Silver as SIL, SLV, SIVR Keep Shining on Higher Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2542134893","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542134893?lang=en_us&edition=fundamental","pubTime":"2025-06-10 18:16","pubTimestamp":1749550589,"startTime":"0","endTime":"0","summary":"Silver-focused ETFs may lack the luster of their golden counterparts, but holders shouldn’t feel second best this year. Silver Service The Silver S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/hi-ho-silver-as-sil-slv-sivr-keep-shining-on-higher-prices?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/hi-ho-silver-as-sil-slv-sivr-keep-shining-on-higher-prices?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SIVR","SIL","BK4588","SLV","BK4547","BK4585"],"gpt_icon":0},{"id":"2539789726","title":"Promising Future for Silexion Therapeutics: Buy Rating Reiterated Due to SIL-204’s Potential in KRAS-Mutated Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2539789726","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539789726?lang=en_us&edition=fundamental","pubTime":"2025-05-31 22:25","pubTimestamp":1748701524,"startTime":"0","endTime":"0","summary":"Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Silexion Therapeutics (SLXN – Research Report). The associated price target r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-future-for-silexion-therapeutics-buy-rating-reiterated-due-to-sil-204s-potential-in-kras-mutated-cancers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-future-for-silexion-therapeutics-buy-rating-reiterated-due-to-sil-204s-potential-in-kras-mutated-cancers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SIL","LENZ"],"gpt_icon":0},{"id":"2531788297","title":"Aclarion Announces Commercial Agreement with Spine Institute of Louisiana","url":"https://stock-news.laohu8.com/highlight/detail?id=2531788297","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531788297?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:00","pubTimestamp":1745920800,"startTime":"0","endTime":"0","summary":"Expands access to first customer using Philips MR Spectroscopy , demonstrating ease of Nociscan integration across multiple MRS platforms. Nociscan now commercially available at 17 sites covering eight states and four countries. Chronic low back pain  is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aclarion-announces-commercial-agreement-spine-100000699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACON","BK4167","SIL","ACONW"],"gpt_icon":0},{"id":"2530947140","title":"Americas Gold & Silver to Be Included in Solactive Global Silver Miners Index (SIL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530947140","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530947140?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"TORONTO, April 28, 2025----Americas Gold and Silver Corporation   is pleased to announce that the Company has been included in the Solactive Global Silver Miners Index  effective May 1, 2025.Paul Huet, Chairman & CEO of Americas, commented: \"The Americas team is very pleased to have met the criteria for inclusion in the Solactive Global Silver Miners Index, which includes having significant silver mining activities, significant revenue from silver mining, and meeting the market capitalization threshold. Our inclusion in the Silver Index represents further validation of our success in building a strong foundation for the Company as a growing silver miner. Inclusion on this major silver index has the potential to attract additional institutional investment into the company and increase liquidity, as the Silver Index is an important benchmark requirement for many large investment funds.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/americas-gold-silver-included-solactive-110000669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAS","SIL","BK4168"],"gpt_icon":0},{"id":"2524781345","title":"BUZZ-Silver miners fall after Trump's tariffs raise demand concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2524781345","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524781345?lang=en_us&edition=fundamental","pubTime":"2025-04-04 23:06","pubTimestamp":1743779209,"startTime":"0","endTime":"0","summary":"BUZZ-Silver miners fall after Trump's tariffs raise demand concerns** Shares of silver miners fall, tracking a sharp decline in prices of the metal** Spot silver XAG= slips 7.1% to $29.56 an ounce, headed for its worst week since September 2020** Prices fall as concerns about demand for the industrial precious metal dominated sentiment due to recession fears stemming from U.S. President Donald Trump's slew of tariffs** Coeur Mining CDE.N and Hecla Mining HL.N down 10.8% and 11.5%, respectively** Canadian miners Wheaton Precious Metals WPM.TO down 6.2%, MAG Silver MAG.TO slips 9.8%, Fortuna Mining FVI.TO down 11.1% and Endeavour Silver EDR.TO loses 12.3%** ETFs Abrdn Physical Silver SIVR.P and iShares Silver Trust SLV.P both down 5.9%; Global X Silver Miners SIL.P loses 9.8% and ProShares Ultra Silver AGQ.P drops 11.7%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nL3N3QI112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","LU0345780281.USD","LU0345780521.USD","SLV","SIVR","SIL","BK4210","BK4585","BK4570","BK4017","AGQ","CDE","HL","BK4588"],"gpt_icon":0},{"id":"2522035556","title":"ETF investors appear hungry for international stocks despite looming tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2522035556","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522035556?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:59","pubTimestamp":1743116340,"startTime":"0","endTime":"0","summary":"The SPDR Euro STOXX 50 ETF is crushing the S&P 500 so far in 2025. Thank you for your interest in ETF Wrap, and for making it a part of your weekly reading over the years.After March 27, MarketWatch will no longer publish the ETF Wrap newsletter. While this newsletter will end, MarketWatch will continue to bolster our core coverage of ETFs and other investing trends that affect your wallet, ensuring that you receive the sharpest insights and analysis every day from MarketWatch.Find our world-class journalism and insights at MarketWatch.com, where our coverage of ETFs will be stronger and more focused than ever.  To explore our variety of newsletter offerings covering how the news of the day impacts you and your money, visit MarketWatch's Newsletter Center.Amid the upheaval of shifting U.S. trade policy, exchange-traded-fund investors are turning to international stocks despite looming tariffs.Yet U.S.-listed ETFs focused on total-market equities in developed Europe have seen $4.9 billi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLY","VXUS","MSTY","ETHE","TAN","LCAP","BK4516","CQQQ","NVDY","STRK","SILJ","ARKK","BK4570","CONY","LU0963586101.USD","BK4596","SCO","UCO","SIL","BK4585","GDX","FEZ","SHLD","BFRE","BK4023","BK4600","ETHA","BK4504","GDXJ","BK4588","BK4544","BK4595","FXI","BK4550","USO","BK4601","ARKW","FDN","MCHI"],"gpt_icon":1},{"id":"2522067085","title":"Global X Silver Miners ETF (SIL): Among The Best Global ETFs To Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522067085","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522067085?lang=en_us&edition=fundamental","pubTime":"2025-03-25 05:21","pubTimestamp":1742851310,"startTime":"0","endTime":"0","summary":"We recently published a list of 12 Best Global ETFs to Buy. In this article, we are going to take a look at where Global X Silver Miners ETF  stands against other best global ETFs.The ETF industry experienced remarkable growth in 2024, with global assets under management  reaching $14.8 trillion by the fourth quarter. While strong equity market performance contributed to this increase, record-breaking net inflows of $1.88 trillion were the primary driver. This growth was fueled by innovation from ETF and ETP providers, along with increasing investor adoption across different markets, investment styles, and investor types. The factors that have supported the industry’s expansion over the past 30 years, such as transparency, competitive fees, liquidity, and tax benefits in regions like the US, Ireland, and Luxembourg, continue to attract capital.Noel Archard, Global Head of ETFs and Portfolio Solutions at AllianceBernstein, highlighted key trends shaping the ETF market in 2025. Growth is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-x-silver-miners-etf-212150006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0612318971.USD","BK4017","LU1430597077.USD","WPM","FDN","SIL","BK4585","BK4588","LU0612318385.USD","BK4550","LU0654597011.USD"],"gpt_icon":0},{"id":"2521216490","title":"Have You Missed Out on Gold's Record Run? Take a Look at Silver","url":"https://stock-news.laohu8.com/highlight/detail?id=2521216490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521216490?lang=en_us&edition=fundamental","pubTime":"2025-03-23 10:33","pubTimestamp":1742697213,"startTime":"0","endTime":"0","summary":"Fundamentals favor a 'serious and powerful' run in silver prices: analyst. When it comes to investing in precious metals, silver might be an afterthought, given gold's run to record intraday highs 15 times so far this year.\"Silver is a hidden, precious gem that should be considered by investors looking for opportunity to play gold and silver bull markets,\" said Peter Spina, founder and president of investor websites GoldSeek.com and SilverSeek.com.For now, silver  , which is a much smaller market in terms of trading volume, has lagged the rise in gold  .Year to date, silver was up 14.5% - barely above gold's climb of 14.4%.Trevor Yates, senior investment analyst at Global X, believes that the most notable aspect of silver right now is \"just how inexpensive it is relative to gold.\". The ratio between the two metals has averaged around 70 ounces of silver to 1 ounce of gold since the late 1980s, according to a January report from Sprott, which said the current high ratio indicates that s","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","SIL","FSM","PAAS","MAG","SVM"],"gpt_icon":1},{"id":"2517185051","title":"Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185051?lang=en_us&edition=fundamental","pubTime":"2025-03-07 04:26","pubTimestamp":1741292763,"startTime":"0","endTime":"0","summary":"Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report) and keeping the price target at $9.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/silexion-therapeutics-receives-buy-rating-from-naz-rahman-following-promising-sil-204-pre-clinical-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/silexion-therapeutics-receives-buy-rating-from-naz-rahman-following-promising-sil-204-pre-clinical-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SIL","LENZ"],"gpt_icon":0},{"id":"2514875052","title":"Hexagon ramps up ADAS software innovation with cloud-native quality test automation solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2514875052","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514875052?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:39","pubTimestamp":1740649140,"startTime":"0","endTime":"0","summary":"New cloud solution simplifies ADAS software testing by integrating comprehensive 'real world' vehicle environment and safety scenarios into automated continuous software integration and testing workflows. From an intuitive web interface, ADAS engineers can easily create and configure their system under test  such as ADAS algorithms. They can validate their SUT with highly accurate physics-based simulations from Hexagon's environment simulation engine that leverages its 15 years of domain expertise. When developers run a test, VTDx executes the OpenDRIVE and OpenSCENARIO standard compliant software-in-the-loop  test programmes. By orchestrating tens or thousands of simulations — of as many scenarios as needed — automatically and simultaneously, companies can significantly reduce delays in configuration and computing time for their standardised SIL test programmes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hexagon-ramps-adas-software-innovation-093900397.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hexagon-ramps-adas-software-innovation-093900397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HXGBY","HXGBF","BK4157","SIL"],"gpt_icon":0},{"id":"2514094309","title":"Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2514094309","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514094309?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks. Grand Cayman, Cayman Islands, Feb. 25, 2025  -- Silexion Therapeutics Corp.  , a clinical-stage biotechnology company pioneering RNA interference  therapies for KRAS-driven cancers, today announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This milestone represents the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models.The study specifically evaluated two critical aspects of SIL-204's potential therapeutic profile:. SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas. \"Completing this initial study in orthotopic models represents a significant milestone in our","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-announces-completion-initial-133000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLXN","LENZ","BK4139","SIL","SLXNW"],"gpt_icon":0},{"id":"2506515267","title":"Silexion Therapeutics reports preclinical data for SIL-204","url":"https://stock-news.laohu8.com/highlight/detail?id=2506515267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506515267?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:36","pubTimestamp":1738071379,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-reports-preclinical-data-for-sil-204?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-reports-preclinical-data-for-sil-204?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SIL","LENZ","SLXN","BK4139"],"gpt_icon":0},{"id":"2506516350","title":"Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2506516350","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506516350?lang=en_us&edition=fundamental","pubTime":"2025-01-28 21:29","pubTimestamp":1738070940,"startTime":"0","endTime":"0","summary":"New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/28/3016377/0/en/Silexion-Therapeutics-Reports-Strong-Tumor-Growth-Reduction-from-Systemic-Administration-of-SIL-204-in-Preclinical-Pancreatic-Cancer-Models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIL","BK4139","LENZ","SLXN"],"gpt_icon":0},{"id":"2504091454","title":"PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2504091454","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504091454?lang=en_us&edition=fundamental","pubTime":"2025-01-17 00:04","pubTimestamp":1737043440,"startTime":"0","endTime":"0","summary":"KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies, showcasing its potential to transform outcomes in these hard-to-treat cancers.The newly released data reveal significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine. In human pancreatic tumor cell models harboring KRAS G12D mutations, SIL-204 amplified the efficacy of these standard therapies, resulting in greater reductions in cancer cell confluence compared to chemotherapy alone. This underscores SIL-204’s potential to enhance treatment regimens for pancreatic cancer and other KRAS-driven cancers, potentially addressing a substantial unmet medical need.As KRAS-driven cancers continue to be among the most aggressive and elusive to treat, Silexion’s progress with SIL-204 positions it as an important innovator to watch in the prec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-market-silexion-therapeutics-sil-160400748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLXN","LENZ","BK4211","HOPE","BK4139","SIL","SLXNW"],"gpt_icon":0},{"id":"2503779126","title":"Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2503779126","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503779126?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:01","pubTimestamp":1736974860,"startTime":"0","endTime":"0","summary":"Significant new preclinical results demonstrate synergistic activity of SIL-204 with 5-fluorouracil and irinotecan as well as gemcitabine, reinforcing its potential to improve outcomes in KRAS-mutated","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/15/3010424/0/en/Silexion-Therapeutics-Announces-Additional-Promising-Preclinical-Data-for-SIL-204-Demonstrating-Impressive-Synergy-with-First-Line-Pancreatic-Cancer-Chemotherapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SIL","LENZ"],"gpt_icon":0},{"id":"2503640306","title":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2503640306","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503640306?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:50","pubTimestamp":1736772600,"startTime":"0","endTime":"0","summary":"Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers. Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp.  , a clinical-stage biotech developing RNA interference  therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal  Cancers Symposium taking place January 23-25, 2025, in San Francisco, California.Silexion’s abstract will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025. Following the presentation, the poster will be available on Silexion Therapeutics’ website under the “Our Science” section.Title: SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation Presenter: Mitchell Shirvan, Ph.D. Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Abstract Nu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silexion-therapeutics-present-sil-204-125000076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SLXN","LENZ","SIL","SLXNW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SIL\",params:#limit:5,,,undefined,":[{"date":"2024-12-30","symbol":"SIL","amount":0.757701,"announcedDate":"2024-12-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Silver Miners Etf","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-07","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2025-01-07"},{"date":"2024-06-27","symbol":"SIL","amount":0.00552,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"Silver Miners Etf","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-05","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-07-05"},{"date":"2023-12-28","symbol":"SIL","amount":0.137416,"announcedDate":"2023-12-27","type":"dividend","market":"US","newRecordDate":"2023-12-29","defaultRemindTime":1703773800000,"name":"Silver Miners Etf","recordDate":"2024-01-08","payableDate":"2023-12-29","currency":"USD","dateTimestamp":1703739600000,"payDate":"2024-01-08"},{"date":"2023-06-29","symbol":"SIL","amount":0.031298,"announcedDate":"2023-06-28","type":"dividend","market":"US","newRecordDate":"2023-06-30","defaultRemindTime":1688045400000,"name":"Silver Miners Etf","recordDate":"2023-07-10","payableDate":"2023-06-30","currency":"USD","dateTimestamp":1688011200000,"payDate":"2023-07-10"},{"market":"US","date":"2022-12-29","symbol":"SIL","amount":0.063214,"defaultRemindTime":1672324200000,"name":"Silver Miners Etf","recordDate":"2023-01-09","payableDate":"2022-12-30","currency":"USD","type":"dividend","dateTimestamp":1672290000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SIL\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-08","value":0.070388,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-06","value":1.0728519,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-09","value":0.006492,"currency":"USD"},{"executeDate":"2018-12-28","recordDate":"2018-12-31","paymentDate":"2019-01-08","value":0.303918,"currency":"USD"},{"executeDate":"2019-06-27","recordDate":"2019-06-28","paymentDate":"2019-07-08","value":0.098263,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SIL\",market:\"US\",delay:true,,,undefined,":{}}}